Provided by Tiger Trade Technology Pte. Ltd.

Pfizer

27.96
-0.0600-0.21%
Volume:27.18M
Turnover:758.93M
Market Cap:158.97B
PE:36.80
High:28.02
Open:28.00
Low:27.77
Close:28.02
52wk High:28.75
52wk Low:23.58
Shares:5.69B
Float Shares:5.64B
Volume Ratio:0.85
T/O Rate:0.48%
Dividend:1.72
Dividend Rate:6.15%
EPS(TTM):0.7599
EPS(LYR):1.36
ROE:5.01%
ROA:5.78%
PB:1.87
PE(LYR):20.49

Loading ...

Pfizer reports Q2 adjusted EPS 77c, consensus 68c

TIPRANKS
·
Aug 04

Pfizer backs FY26 adjusted EPS view $2.80-$3.00, consensus $2.95

TIPRANKS
·
Aug 04

Pfizer announces expansion of productivity enhancement Initiatives

TIPRANKS
·
Aug 04

Pfizer Beats Earnings Estimates, Targets $2.5 Billion in Additional Cost Cuts

Reuters
·
Aug 04

Pfizer Says Q2 2026 Results Beat Expectations on Non-COVID Brand Growth and Cost Discipline

Reuters
·
Aug 04

Pfizer- Plan to Advance Phase 3 Program for Berobenatide That Includes 10 Studies for Chronic Weight Management, Obesity-Related Conditions This Year

THOMSON REUTERS
·
Aug 04

Pfizer - Aim Delivering Risk-Adjusted High Single-Digit Revenue Cagr from Year-End 2028 Through Year-End 2033- Prepared Remarks

THOMSON REUTERS
·
Aug 04

Pfizer: Expect a Pivotal Trial Start This Year Investigating Nurtec’s Use as a Treatment for Chronic Migraine- Prepared Remarks

THOMSON REUTERS
·
Aug 04

Pfizer - Targeting First Berobenatide Approval in 2028 - Prepared Remarks

THOMSON REUTERS
·
Aug 04

Pfizer - Powered in Part by Rapid Advancement of Technology, Net Cost Savings from NOW Expected to Total $6.7 Bln Through 2029 - Prepared Remarks

THOMSON REUTERS
·
Aug 04

Pfizer - We NOW Expect an Additional $1 Billion in Savings from Our Ongoing Cost Realignment Program- Prepared Remarks

THOMSON REUTERS
·
Aug 04

Pfizer: Already Seeing Benefits from AI in Reducing Costs & Expanding Yields in Manufacturing- Prepared Remarks

THOMSON REUTERS
·
Aug 04

Pfizer: Expect Post-2028 Cash Flow to Benefit from Previously Announced Vyndamax Patent Settlement

THOMSON REUTERS
·
Aug 04

Pfizer Q2 FY26 Swings to Net Loss of USD 248 Million; Revenue Rises 3% to USD 15 Billion

Reuters
·
Aug 04

GUIDANCE: (PFE) Pfizer Expects 2026 Adjusted EPS Range $2.80 to $3, vs. FactSet Est of $2.94

MT Newswires Live
·
Aug 04

Pfizer Q2 Adjusted EPS USD 0.77 Vs. IBES Estimate USD 0.68

Reuters
·
Aug 04

Pfizer: in Q2 Eliquis Globally, up 19% Operationally

THOMSON REUTERS
·
Aug 04

Pfizer - Reaffirms Full-Year 2026 Adj Diluted EPS Guidance $2.80-$3

THOMSON REUTERS
·
Aug 04

Pfizer Outlook FY Revenue USD 60,500-62,500 Million VS. Ibes Estimate USD 61,793 Million

THOMSON REUTERS
·
Aug 04

Pfizer Q2 Revenue USD 15,034 Million VS. Ibes Estimate USD 14,412 Million

THOMSON REUTERS
·
Aug 04